CoChat

Practical recommendations and new therapies for Wilson's disease

Brewer, George J. · 1995 · Drugs

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Abstract

Wilson's disease is an inherited disorder of copper accumulation. The basic defect is a failure of excretion of excess copper in the bile by the liver for loss in the stool. The accumulating copper causes damage primarily to the liver and the brain. Patients typically present in the second to the fourth decades of life with liver disease, a neurological disease of the movement disorder type, or a wide array of behavioural disturbances. Because the manifestations of Wilson's disease are so protean, and the disease masquerades so well as something else, recognition of the possibility of Wilson's disease is a major problem, leading to serious underdiagnosis of the disease. Excellent therapies exist for both the prophylaxis and treatment of Wilson's disease. The longer recognition and diagnosis are delayed, the greater the risk of permanent damage to liver and/or brain. The availability of effective therapy and the risks in delay or therapy make the earliest possible diagnosis critical. Once the disease comes under consideration, a series of diagnostic steps can be undertaken which almost always establish or rule out the diagnosis of Wilson's disease. These include urine copper, blood ceruloplasmin, slit lamp examination for Kayser-Fleischer rings, and liver biopsy with quantitative copper assay. Currently, there are 4 drugs being used as anticopper agents in Wilson's disease. These are zinc, which blocks intestinal absorption of copper, penicillamine and trientine, both of which are chelators that increase urinary excretion of copper, and tetrathiomolybdate which forms a tripartite complex with copper and protein, and can block copper absorption from the intestine, or render blood copper non-toxic. Zinc is clearly the treatment of choice, in our opinion, for maintenance therapy, for the treatment of the presymptomatic patient from the beginning and for the treatment of the pregnant patient, because of its complete efficacy and lack of toxicity. For the initial treatment of the patient presenting with mild liver failure, we empirically use a combination of trientine and zinc. Trientine gives a strong, fast, negative copper balance, and zinc induces hepatic metallothionein, which sequesters hepatic copper. For the initial treatment of patients presenting with neurological disease we use an experimental drug, tetrathiomolybdate, which provides rapid, safe control of copper. These latter patients are at great risk of serious permanent neurological worsening with penicillamine, and zinc is too slow-acting, in our judgment, to be optimal.

Overview

Integrity signals

Registry

Crossref · 10.2165/00003495-199550020-00004

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

2 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 50 references

Cited by

See all 95

Metadata

Authors
Brewer, G. J.
Affiliations
University of Michigan (US)
Corresponding author
Brewer, George J.
Venue
Drugs
Published
1995-08
Volume
50
Issue
2
Pages
240-249
ISSN
0012-6667 (ISSN-L)
OpenAlex
W2032185349
Cited by
92
References
50
Citations by year
2026: 1 · 2025: 1 · 2023: 1 · 2020: 2 · 2019: 3 · 2018: 1 · 2016: 2 · 2015: 1 · 2014: 6 · 2013: 1 · 2012: 4
FWCI
5.23
Type
journal article
Language
en
Open access
closed
Locations
  • Drugs (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • U.S. Food and Drug Administration (FD-U-000505, FD-R-000179)
  • National Center for Research Resources (M-O1-RR-00042, M01RR000042)
Topics
  • Health Sciences › Nursing › Nutrition and Dietetics › Trace Elements in Health
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
  • Life Sciences › Neuroscience › Neurology › Neurological diseases and metabolism
Keywords
Wilson's disease, copper accumulation, copper chelation, zinc therapy, D-penicillamine, triethylenetetramine, tetrathiomolybdate, ceruloplasmin, Kayser-Fleischer rings, underdiagnosis, metallothionein, maintenance therapy
MeSH terms
Chelating Agents, Copper, Female, Hepatolenticular Degeneration, Humans, Liver, Metallothionein, Molybdenum, Penicillamine, Pregnancy, Trientine, Zinc

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Practical recommendations and new therapies for Wilson's disease. https://app.cochat.ai/papers/10.2165/00003495-199550020-00004
The paper
Brewer, G. J. (1995). Practical recommendations and new therapies for Wilson's disease. Drugs. https://doi.org/10.2165/00003495-199550020-00004

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.